Table 2.

Prostate cancer incidence by use of cholesterol-lowering drugs, Cancer Prevention Study II Nutrition Cohort, 1997 to 2003

Never useFormer useCurrent use, <5 yCurrent use, ≥5 y
All prostate cancers
    RR (95% CI)1.00 (Reference)0.88 (0.72-1.07)1.02 (0.92-1.13)1.06 (0.93-1.20)
    Cases/person-years2,350/193,971114/10,925559/47,009390/32,147
Stage II, low grade*
    RR (95% CI)1.00 (Reference)0.79 (0.62-0.99)1.03 (0.92-1.16)1.13 (0.98-1.30)
    Cases/person-years1,825/193,97179/10,925441/47,009321/32,147
Stage II, high grade
    RR (95% CI)1.00 (Reference)1.40 (0.85-2.31)1.10 (0.81-1.5)1.03 (0.70-1.51)
    Cases/person-years250/193,97118/10,92563/47,00942/32,147
Advanced prostate cancer
    RR (95% CI)1.00 (Reference)1.05 (0.59-1.87)0.92 (0.65-1.30)0.60 (0.36-1.00)
    Cases/person-years239/193,97113/10,92546/47,00919/32,147
  • NOTE: Data were adjusted for age, race, education, BMI, NSAID use, history of PSA testing, elevated cholesterol, history of diabetes, history of heart attack, and family history of prostate cancer.

  • * American Joint Committee on Cancer stage II (organ confined), and Gleason score of 7 or less.

  • American Joint Committee on Cancer stage II (organ confined), and Gleason score of 8 or more.

  • American Joint Committee on Cancer stage III or IV, or fatal prostate cancer of unknown stage at diagnosis.